 Artist: Something Corporate: mp3 download Genre(s): ROck: Alternative Rock Something Corporate's discography:  North Year: 2003 Tracks: 12  Songs For Silent Movies Year: Tracks: 7 Of the myriad georges Jacques Danton True Young alt-rock bands to uprise in the other 2000s, Something Corporate stood out and showed tremendous potential difference drop. On one handwriting, the bandmembers were barely out of high gear wheel school when the prestigious Cali indie punk label Drive-Thru signed them, which helped Something Corporate plug into with a turgid interview of West Coast adolescent hipsters look for a band to claim as their possess. On the other book, though, the band didn't play goon rock; they played refined, literate, radio-ready alt-rock -- a vendible intelligent that MCA recognised just before connecting with the dance orchestra for a debut EP, Audioboxer. Released in tardy 2001, Audioboxer featured only sixer songs yet showcased the band's prognosticate as it synthesized post-grunge alt-rock guitar grind with a bit of torrid emo-styled songwriting and singing. It as well didn't hurt that the dance orchestra boasted a bona fide poster son in Andrew McMahon, a anthesis giving. Before the Orange County, CA, band became Something Corporate, McMahon, drummer Brian Ireland, and bassist Clutch played in some other dance orchestra they had started to contend in a high gear school struggle of the bands. And even though they north Korean won the battle, the isthmus didn't last too long. The turn point came when McMahon met guitarist Josh Partington at a high schooling party. With a renewed sentiency of enthusiasm, the teens started electronic jamming together as Something Corporate. Soon they added guitar player William Tell and were playing local clubs; non shortly after, they were playing one-off gigs opening move for bands like Sugar Ray and Better Than Ezra. Around this time, Drive-Thru came knocking, and even though the label was known primarily as a youth punk rocker label and Something Corporate was far from that, the partnership made sense -- Drive-Thru recognised the band's potential as a crossover move and Something Corporate recognised the label's reputation as a well-thought-of indie. MCA then came into the mental picture in the first place as a distributor, though the major pronounce did role its punch to securities industry the set. Their summer-tinged debut full-length, Going Through the Window, divided up both son and appeared in natural spring 2002. Subsequent touring followed before their slightly darker soph feat, Frederick North, was issued in October 2003. Guitar player William Tell amicably left the grouping in early 2004 to work on on solo corporeal, concisely ahead Something Corporate headed out on a nationwide co-headlining tour of duty with Yellowcard. Bob Anderson (erstwhile of River City High) replaced Tell on the spell; a resilient DVD, Live at the Ventura Theater, was side by side released in November 2004. Aside from playing plenitude of shows, McMahon likewise took time out to exercise on his solo project, Jack's Mannequin. The debut Mannequin record came out in late summertime 2005, just a load-bearing tour was canceled subsequently McMahon was diagnosed with intense lymphoblastic leukemia in June. Touring for both bands was then pose on prevail piece he went through treatment; by the year's end, he had recovered from a successful bone bone marrow transplant from his sister. McMahon then turned his attention to the Jack's Mannequin propose, touring in support of their debut record album, Everything in Transit, which had humiliated into the Billboard Top 40. |
Sunday, 7 September 2008
Mp3 music: Something Corporate
Thursday, 28 August 2008
NovaRx Initiates Pivotal Phase III Clinical Trial In Lung Cancer Patients
�NovaRx Corporation announced
that the companionship initiated its pivotal Phase III clinical trial of
Lucanix(R) (belagenpumatucel-L) in the treatment of advanced non-small cell
lung cancer (NSCLC). The first patient enrolled in the study was treated by
Dr. Lyudmila Bazhenova the trial's principal investigator at the University
of California, San Diego School of Medicine.
The study is designated as the STOP trial because of its expected
endpoints: Survival; Tumor-free, Overall; and Progression-free. It is an
international, multicenter, randomized, double blind study involving up to
700 individuals with advanced stage NSCLC, and testament be conducted at
or so 90 clinical sites in the U.S., Canada, India, and Europe.
In a Phase II clinical visitation, two-year survival among patients with
stages IIIB and IV disease who received Lucanix(R) was significantly thirster
than that of individuals being tempered with the current standard of care. A
second, investigator-initiated stage II study supported these results.
In contrast to conventional crab therapies, where systemic
chemotherapeutic drugs nonspecifically kill normal cells as well as tumor
cells, the therapeutical vaccine developed by NovaRx induces the patient's
immune system to specifically target the genus Cancer. In phase II clinical
studies to date, the side effects of this treatment have included rubor
or tenderness at the injection situation.
"In aesculapian research, you see something like this once in a lifetime,"
said John Nemunaitis, M.D., executive theatre director at the Mary Crowley Medical
Research Center in Dallas, TX and principal investigator of both the Phase
II Lucanix(R) written report and the investigator-initiated Phase II trial.
"This is a very promising plan of attack to crab treatment, and results
reported so far are beyond anyone's expectations. I am very excited to be a
part of this confirmatory exploit, and to be able to proffer this unique
treatment option to my patients," said Dr. Lyudmila Bazhenova, principal
investigator of the STOP trial at the Rebecca and John Moore's Cancer
Center of UCSD. "Traditional chemotherapy for stage IV NSCLC noneffervescent yields
unsatisfying results, and my leslie Townes Hope is that this trial will improve the
natural history of the disease." The FDA granted NovaRx Fast-Track approval
for the Lucanix(R) tryout in March of 2007, and Special Protocol Assessment
approval in January of 2008.
According to the American Cancer Society, in 2008 there will be an
estimated 215,000 new cases of lung cancer diagnosed, and 162,000 deaths
caused by this disease in the United States alone. Lung cancer is the
identification number one grounds of cancer death throughout the world. "The statistics for
orbicular lung cancer deaths are staggering. I am positive that this Phase
III trial testament establish Lucanix(R) as a viable intervention option for
patients with this direful disease," aforementioned Dr. Habib Fakhrai, president and
cofounder of NovaRx.
In Phase II testing, 50 percent of patients entering the trial with
stable disease who standard Lucanix(TM) following one frontline regimen of
chemotherapy lived more than 44 months, compared to less than 10-12 months
for such patients under the current standard of care. In addition, patients
with advanced disease world Health Organization received Lucanix(TM) after zero to five prior
chemotherapy treatments demonstrated a annual survival of 61 pct and
a two-year survival of 41 percent. Such late-stage patients typically
exhibit one-year survival of less than 30 percent. Lucanix(TM) was
shown to acquire only insignificant side effects.
"In addition to significantly increased survival," Fakhrai continued,
"we saw virtually no side personal effects in the patients treated in phase angle II
trials. Based on our previous trial results, we think Lucanix(R) may lead
to a significant advancement in patient charge. We appear forward to continuing
to enroll patients in this very important clinical study."
"We are delighted to have been selected as one of the major centers to
test this highly bright immunotherapeutic approach path to treating
individuals with NSCLC," aforementioned Dr. Julian Molina, star investigator of
the STOP Trial at Mayo Clinic in Rochester, Minnesota.
Lucanix(R) consists of four non-small cell lung cancer cellular phone lines that
have been genetically engineered to close off their immune suppressive
properties. These cell lines are then modified to block a molecule called
transforming growth factor-beta (TGF-beta), which is commonly produced by
cancer cells as a cloak against the body's natural immune system. When
TGF-beta is blocked, the immune system tin mount an anti-tumor response.
The results of Phase II examination were published in the October 10, 2006
edition of the Journal of Clinical Oncology.
Studies to test the therapeutic vaccinum in other types of cancer ar
also in progress. "NovaRx remains committed to developing whole cellbased
therapeutic vaccines for whatsoever form of cancer in which this approach may
significantly meliorate patient outcomes by either curing their disease
entirely, or by stabilizing it over the course of their lives," said Justin
Murdock, CEO and chairman of the board of NovaRx.
Founded in 1997, NovaRx Corp. is a clinical-stage biopharmaceutical
company dedicated to the discovery, development, and commercialization of
novel cell-based therapeutic vaccines for the treatment of cancer. The
company's 24,000 square foot headquarters in San Diego, CA, house corporate
offices and manufacture operations. The proprietary core technology upon
which Lucanix(R) is based has been exclusively accredited to NovaRx on a
worldwide base. Lucanix(R) is a trademark of NovaRx Corp.
For more information on the NovaRx Lucanix(R) Phase III STOP Trial in
NSCLC please bring down http://www.NovaRx.com.
NovaRx Corporation
http://www.NovaRx.com
More info
that the companionship initiated its pivotal Phase III clinical trial of
Lucanix(R) (belagenpumatucel-L) in the treatment of advanced non-small cell
lung cancer (NSCLC). The first patient enrolled in the study was treated by
Dr. Lyudmila Bazhenova the trial's principal investigator at the University
of California, San Diego School of Medicine.
The study is designated as the STOP trial because of its expected
endpoints: Survival; Tumor-free, Overall; and Progression-free. It is an
international, multicenter, randomized, double blind study involving up to
700 individuals with advanced stage NSCLC, and testament be conducted at
or so 90 clinical sites in the U.S., Canada, India, and Europe.
In a Phase II clinical visitation, two-year survival among patients with
stages IIIB and IV disease who received Lucanix(R) was significantly thirster
than that of individuals being tempered with the current standard of care. A
second, investigator-initiated stage II study supported these results.
In contrast to conventional crab therapies, where systemic
chemotherapeutic drugs nonspecifically kill normal cells as well as tumor
cells, the therapeutical vaccine developed by NovaRx induces the patient's
immune system to specifically target the genus Cancer. In phase II clinical
studies to date, the side effects of this treatment have included rubor
or tenderness at the injection situation.
"In aesculapian research, you see something like this once in a lifetime,"
said John Nemunaitis, M.D., executive theatre director at the Mary Crowley Medical
Research Center in Dallas, TX and principal investigator of both the Phase
II Lucanix(R) written report and the investigator-initiated Phase II trial.
"This is a very promising plan of attack to crab treatment, and results
reported so far are beyond anyone's expectations. I am very excited to be a
part of this confirmatory exploit, and to be able to proffer this unique
treatment option to my patients," said Dr. Lyudmila Bazhenova, principal
investigator of the STOP trial at the Rebecca and John Moore's Cancer
Center of UCSD. "Traditional chemotherapy for stage IV NSCLC noneffervescent yields
unsatisfying results, and my leslie Townes Hope is that this trial will improve the
natural history of the disease." The FDA granted NovaRx Fast-Track approval
for the Lucanix(R) tryout in March of 2007, and Special Protocol Assessment
approval in January of 2008.
According to the American Cancer Society, in 2008 there will be an
estimated 215,000 new cases of lung cancer diagnosed, and 162,000 deaths
caused by this disease in the United States alone. Lung cancer is the
identification number one grounds of cancer death throughout the world. "The statistics for
orbicular lung cancer deaths are staggering. I am positive that this Phase
III trial testament establish Lucanix(R) as a viable intervention option for
patients with this direful disease," aforementioned Dr. Habib Fakhrai, president and
cofounder of NovaRx.
In Phase II testing, 50 percent of patients entering the trial with
stable disease who standard Lucanix(TM) following one frontline regimen of
chemotherapy lived more than 44 months, compared to less than 10-12 months
for such patients under the current standard of care. In addition, patients
with advanced disease world Health Organization received Lucanix(TM) after zero to five prior
chemotherapy treatments demonstrated a annual survival of 61 pct and
a two-year survival of 41 percent. Such late-stage patients typically
exhibit one-year survival of less than 30 percent. Lucanix(TM) was
shown to acquire only insignificant side effects.
"In addition to significantly increased survival," Fakhrai continued,
"we saw virtually no side personal effects in the patients treated in phase angle II
trials. Based on our previous trial results, we think Lucanix(R) may lead
to a significant advancement in patient charge. We appear forward to continuing
to enroll patients in this very important clinical study."
"We are delighted to have been selected as one of the major centers to
test this highly bright immunotherapeutic approach path to treating
individuals with NSCLC," aforementioned Dr. Julian Molina, star investigator of
the STOP Trial at Mayo Clinic in Rochester, Minnesota.
Lucanix(R) consists of four non-small cell lung cancer cellular phone lines that
have been genetically engineered to close off their immune suppressive
properties. These cell lines are then modified to block a molecule called
transforming growth factor-beta (TGF-beta), which is commonly produced by
cancer cells as a cloak against the body's natural immune system. When
TGF-beta is blocked, the immune system tin mount an anti-tumor response.
The results of Phase II examination were published in the October 10, 2006
edition of the Journal of Clinical Oncology.
Studies to test the therapeutic vaccinum in other types of cancer ar
also in progress. "NovaRx remains committed to developing whole cellbased
therapeutic vaccines for whatsoever form of cancer in which this approach may
significantly meliorate patient outcomes by either curing their disease
entirely, or by stabilizing it over the course of their lives," said Justin
Murdock, CEO and chairman of the board of NovaRx.
Founded in 1997, NovaRx Corp. is a clinical-stage biopharmaceutical
company dedicated to the discovery, development, and commercialization of
novel cell-based therapeutic vaccines for the treatment of cancer. The
company's 24,000 square foot headquarters in San Diego, CA, house corporate
offices and manufacture operations. The proprietary core technology upon
which Lucanix(R) is based has been exclusively accredited to NovaRx on a
worldwide base. Lucanix(R) is a trademark of NovaRx Corp.
For more information on the NovaRx Lucanix(R) Phase III STOP Trial in
NSCLC please bring down http://www.NovaRx.com.
NovaRx Corporation
http://www.NovaRx.com
More info
Friday, 8 August 2008
Mya Blames Cash Issues For Missed Show
R+B vocalizer MYA has slammed reports her "diva behaviour" caused the cancellation of a recent cabaret gig in Barbados, blaming non-payment for the scrapped show.
The Case of the Ex star was scheduled to host and perform at the Celebrity Party event at Club NXS earlier this month (Jul08).
However, she pulled out days before the gig after learning the event promoter had a lack of funds, and was thus unable to pay her for the appearance.
Mya was heavily criticised by partygoers for the late cancellation - but she insists it wasn't her fault, and has apologised to her fans for the incident.
In a statement released on behalf of the star, her attorney Paul Gardner says, "A workweek and a half prior to the scheduled appearing at Club NXS in St. Lawrence Gap, Mya was informed that the promoter of this event did non have the funds available to oblige her appearance.
"Despite this, the promoters of the 'Celebrity Party' went on to include Mya on the promotional material, and to announce her appearance on the local radiocommunication station. Because of the lack of funding, Mya was no longer obligated to appear at this event.
"Furthermore, in addition to a last second meet and greet with young students and athletes, Mya attended a dinner organised by the local radio station. Unbeknownst to her the radio station had advertised her presence as the prize for two contest winners. Mya graciously attended this dinner, even though this she was not required to do so under the contract.
"Mya would like to apologise to her fans for the confusion and letdown caused by this position. However, she would also like her fans to know that she takes her professional engagements selfsame seriously, and would have attended this event had it been organised right and if the promoter had the originally in agreement upon pecuniary compensation available."
More information
Tuesday, 1 July 2008
Girl Talk maps fall tour dates
Girl Talk aka Greg Gillis has announced a string of dates across the US and Canada this fall, kicking off October 9 in Philadelphia.
The dates follow a string of summer shows from Gillis, including slots at the Capitol Hill Block Party in Seattle on July 25, Lollapalooza in Chicago on August 3, and All Points West in New Jersey on August 8 as well as a handful of solo shows.
The tour will run through November 14 when it wraps up in Foxborough, MA.
The dates are:
Boulder, CO Fox Theatre (July 11)
Aspen, CO Belly Up (12)
Victoria, British Columbia �?? Sugar (23)
Vancouver, British Columbia Commodore Ballroom (24)
Seattle, WA Capitol Hill Block Party (25)
Portland, OR Roseland Theater (26)
Chicago, IL Grant Park Lollapalooza (August 3)
Jersey City, NJ Liberty State Park All Points West Festival (8)
Philadelphia, PA Starlight Ballroom (October 9)
Washington, DC 9:30 Club (10)
Baltimore, MD Sonar (11)
Carrboro, NC Cat's Cradle (13)
Asheville, NC Orange Peel (14)
Knoxville, TN Valarium (15)
Atlanta, GA Variety Playhouse (16)
New Orleans, LA House of Blues (17)
Houston, TX Warehouse Live! (18)
Austin, TX Emo's (20)
Dallas, TX Palladium Ballroom (21)
Tucson, AZ Rialto Theater (23)
Los Angeles, CA Henry Fonda Theater (24, 25)
San Francisco, CA The Fillmore (27, 28)
Salt Lake City, UT In the Venue (30)
Denver, CO Odgen Theater (31)
Lawrence, KS The Granada Theatre (November 1)
Minneapolis, MN First Avenue (3)
Milwaukee, WI Turner Hall Ballroom (4)
Urbana, IL Canopy Club (5)
Nashville, TN Cannery Ballroom (6)
Louisville, KY Headliners Music Hall (7)
Cincinnati, OH Bogart's (9)
Cleveland, OH Beachland Ballroom (10)
Pontiac, MI Eagle Theatre (11)
Toronto, Ontario Koolhaus (12)
Montreal, Quebec Club Soda (13)
Foxborough, MA Showcase Live (14)
--By our New York staff.
Find out more about NME.
The dates follow a string of summer shows from Gillis, including slots at the Capitol Hill Block Party in Seattle on July 25, Lollapalooza in Chicago on August 3, and All Points West in New Jersey on August 8 as well as a handful of solo shows.
The tour will run through November 14 when it wraps up in Foxborough, MA.
The dates are:
Boulder, CO Fox Theatre (July 11)
Aspen, CO Belly Up (12)
Victoria, British Columbia �?? Sugar (23)
Vancouver, British Columbia Commodore Ballroom (24)
Seattle, WA Capitol Hill Block Party (25)
Portland, OR Roseland Theater (26)
Chicago, IL Grant Park Lollapalooza (August 3)
Jersey City, NJ Liberty State Park All Points West Festival (8)
Philadelphia, PA Starlight Ballroom (October 9)
Washington, DC 9:30 Club (10)
Baltimore, MD Sonar (11)
Carrboro, NC Cat's Cradle (13)
Asheville, NC Orange Peel (14)
Knoxville, TN Valarium (15)
Atlanta, GA Variety Playhouse (16)
New Orleans, LA House of Blues (17)
Houston, TX Warehouse Live! (18)
Austin, TX Emo's (20)
Dallas, TX Palladium Ballroom (21)
Tucson, AZ Rialto Theater (23)
Los Angeles, CA Henry Fonda Theater (24, 25)
San Francisco, CA The Fillmore (27, 28)
Salt Lake City, UT In the Venue (30)
Denver, CO Odgen Theater (31)
Lawrence, KS The Granada Theatre (November 1)
Minneapolis, MN First Avenue (3)
Milwaukee, WI Turner Hall Ballroom (4)
Urbana, IL Canopy Club (5)
Nashville, TN Cannery Ballroom (6)
Louisville, KY Headliners Music Hall (7)
Cincinnati, OH Bogart's (9)
Cleveland, OH Beachland Ballroom (10)
Pontiac, MI Eagle Theatre (11)
Toronto, Ontario Koolhaus (12)
Montreal, Quebec Club Soda (13)
Foxborough, MA Showcase Live (14)
--By our New York staff.
Find out more about NME.
Sunday, 22 June 2008
Los Planetas
Artist: Los Planetas
Genre(s):
Other
Discography:
Contra La Ley De La Gravedad
Year: 2004
Tracks: 12
Spanish alternative group los Planetas was formed in the other '90s, fashioning their debut EP, called Medusoid, in 1993. Led by J. Penh and guitarist Florent, the band's first gear album was released in 1994 by RCA. It was called Super 8. In January of 1998, los Planetas moved to New York to record Una Semana en el Motor De Un Autobús, followed by 2000's Unidad De Desplazamiento.
'Juno' Star: 'I Feel Weird Being Nominated'
Sunday, 15 June 2008
Britney 'hot' in Pussycat Dolls cameo
Britney Spears looks "hot and blonde" in her cameo appearance in the Pussycat Dolls' new video.
The troubled singer - who has been working hard to get back on track following her alleged breakdown earlier this year - shot her scenes for the girl group’s latest track When I Grow Up in California.
A set source said: "It was carefully planned out.
"In the scene shot, Britney is driving in a car. They all wave at each other as they are passing in traffic - that is it. It is genius and you will love it! Of course, Britney looks hot and blonde."
The Pussycat Dolls filmed the part of the scene in a blue convertible Chevy Imapla.
The insider added: "They are singing and in traffic - looking hot.
"It is a very short sequence, but Britney had a lot of fun with it. Britney really likes the Dolls' music and when she saw them on the MTV Movie Awards at the weekend, she was totally down to do the video."
This is not the first time mother-of-two Britney has teamed up with the group.
She once appeared with the Pussycat Dolls as part of a special performance for her older brother Bryan’s birthday.
See Also
Wednesday, 4 June 2008
Billy Bob Thornton on Angelina Jolie pregnancy: “I�m just so happy for her”
Angelina Jolie’s ex-husband Billy Bob Thornton is full of praise for his former wife.
“I think she was always meant to be a mother in so many ways,” Billy Bob tells Extra. “I�m just so happy for her.”
Jolie married Thornton, whom she had met on the set of Pushing Tin, in May 5, 2000. They split in 2002 shortly after she adopted Maddox, now 6, from Cambodia. Their divorce was finalized a year later, and although the actor was listed as Maddox�s father, Angelina received sole custody, and Brad Pitt officially adopted Maddox in 2006.
See Also
Subscribe to:
Posts (Atom)